Viruses, Vol. 11, Pages 274: Ebola Virus Entry: From Molecular Characterization to Drug Discovery

Viruses, Vol. 11, Pages 274: Ebola Virus Entry: From Molecular Characterization to Drug Discovery Viruses doi: 10.3390/v11030274 Authors: Cristiano Salata Arianna Calistri Gualtiero Alvisi Michele Celestino Cristina Parolin Giorgio Palù Ebola Virus Disease (EVD) is one of the most lethal transmissible infections, characterized by a high fatality rate, and caused by a member of the Filoviridae family. The recent large outbreak of EVD in Western Africa (2013–2016) highlighted the worldwide threat represented by the disease and its impact on global public health and the economy. The development of highly needed anti-Ebola virus antivirals has been so far hampered by the shortage of tools to study their life cycle in vitro, allowing to screen for potential active compounds outside a biosafety level-4 (BSL-4) containment. Importantly, the development of surrogate models to study Ebola virus entry in a BSL-2 setting, such as viral pseudotypes and Ebola virus-like particles, tremendously boosted both our knowledge of the viral life cycle and the identification of promising antiviral compounds interfering with viral entry. In this context, the combination of such surrogate systems with large-scale small molecule compounds and haploid genetic screenings, as well as rational drug design and drug repurposing approaches will prove priceless in our quest for the development of a treatment for EVD.
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research